Other Events ·
On September 8, 2026, Adlai Nortye Group Ltd. announced the dosing of its first patient in Australia for AN4035, a…
ANLAdlai Nortye Group Ltd.
On September 8, 2026, Adlai Nortye Group Ltd. announced the dosing of its first patient in Australia for AN4035, a first-in-class antibody-drug conjugate (ADC) targeting CEACAM5 armed with a pan-RAS(ON) inhibitor payload. This event initiates the global Phase I clinical trial for patients with CEACAM5-enriched RAS-addicted solid tumors. The company also received a 'Study-May-Proceed' letter from the U.S. FDA regarding its investigational new drug application, clearing the path to expand the trial into the United States. Management aims to report full Phase Ia data in the second half of 2027 and is concurrently filing an IND with China's NMPA. Adlai Nortye Group Ltd. operates as a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies.